GlassScriptPhysician profile
Gregory V Marcotte
NPI 1861470767
$16,722.54
in general payments reported to CMS, 2019-2025
46 companies · $2,570 in 2025
The $2,570 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,191 · 2020: $1,546 · 2021: $2,461 · 2022: $2,810 · 2023: $2,368 · 2024: $2,777 · 2025: $2,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,297 · Education: $343 · Consulting Fee: $75.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,296.62 |
| Education | $343.32 |
| Consulting Fee | $75.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,867.22 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,190.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,416.41 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $1,204.51 | 2021-2025 | Orladeyo |
| Pfizer INC. | $1,093.83 | 2019-2025 | |
| Csl Behring | $1,037.63 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $971.28 | 2020-2025 | Hyqvia, Takhzyro, Glassia |
| Genzyme Corporation | $827.58 | 2019-2024 | |
| Genentech USA, INC. | $685.13 | 2019-2025 | Xolair |
| Covis Pharma Gmbh | $485.28 | 2019-2022 | |
| Pharming Healthcare, INC. | $435.68 | 2019-2025 | Ruconest |
| Abbvie INC. | $328.95 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $300.56 | 2019-2025 | |
| Bio Products Laboratory USA, INC. | $290.57 | 2019-2023 | Gammaplex, Coagadex |
| Alk-Abello, INC | $264.06 | 2019-2023 | Grastek, Ragwitek, Odactra |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Marcotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.